Siltuximab Plus Best Supportive Care vs Placebo in Anemic Subjects With Low/Intermediate-1-Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Enrolment: 76 · Results not recorded
Loading the evidence…
Biologic · CLASS-LEVEL identity: siltuximab is the approved chimeric monoclonal antibody that binds and neutralises IL-6 itself (ANTAGONIST, direct interaction, disease efficacy true, first_in_class). ATC L04AC11. DELIBERATE NON-IDENTITY: tocilizumab was retrieved but NOT recorded, because it targets the IL-6 receptor rather than the IL-6 ligand and so does not match 'blocking anti-interleukin-6 antibody'. No trauma-indication trial exists for either.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Myelodysplastic Syndrome
Enrolment: 76 · Results not recorded
Cytokine Release Syndrome · Myeloma
Enrolment: 20 · Results not recorded
High-risk Smoldering Multiple Myeloma
Enrolment: 85 · Results not recorded
Schizophrenia · Psychotic Disorders
Enrolment: 30 · Results not recorded
Critical Illness · Corona Virus Infection · Cytokine Release Syndrome
Enrolment: 860 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute myocardial infarction in mice, with parallel in vitro studies on cultured cardiac fibroblasts
Endogenous IL-6 rapidly but transiently increased HAS1 and HAS2 expression and produced a hyaluronan-rich matrix acutely after acute myocardial infarction. Blocking IL-6 in vivo decreased hyaluronan matrix formation in the peri-infarct region, reduced alpha-smooth muscle actin-positive myofibroblas…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.